Hoe verhoudt SYNT's PE Ratio zich tot zijn concurrenten?

SYNT is duur op basis van de Price-To-Earnings -ratio ( 115.3 x) vergeleken met het gemiddelde van de peer ( 53.2 x).

Hoe verhoudt SYNT's PE Ratio zich tot andere bedrijven in de European Healthcare Services industrie?

SYNT is duur op basis van de Price-To-Earnings -ratio ( 115.3 x) vergeleken met het European Healthcare Services -industriegemiddelde ( 19.1 x).

Wat is SYNT's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

SYNT is duur op basis van de Price-To-Earnings Ratio ( 115.3 x) vergeleken met de geschatte Fair Price-To-Earnings Ratio ( 46.5 x).

Wat is de reële prijs van SYNT als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

SYNT ( SEK27.7 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( SEK42.22 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

SyntheticMR (NGM:SYNT) - Aandelenkoers, Nieuws & Analyse

SYNT Overzicht aandelen

Engages in the development and marketing of imaging solutions for magnetic resonance imaging (MRI) in Sweden, the Middle East, Africa, Europe, North America, South America, and the Asia-Pacific.

Over het bedrijf

SYNT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 34.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 47.4% per jaar groeien

De winst groeide het afgelopen jaar met 70.3%

Risicoanalyse

Aandelen zijn zeer illiquide

Hoog niveau van niet-contante inkomsten

SyntheticMR AB (publ) Concurrenten

RaySearch Laboratories

OM:RAY B

SEK 5.2b

Physitrack

OM:PTRK

SEK 193.5m

Kontigo Care

OM:KONT

SEK 98.7m

Sectra

OM:SECT B

SEK 54.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor SyntheticMR
Historische aandelenkoersen
Huidige aandelenkoers	SEK 27.70
52 Week Hoogtepunt	SEK 34.90
52 Week Laag	SEK 17.30
Bèta	0.96
11 maand verandering	0%
3 maanden verandering	1.09%
1 Jaar Verandering	-13.44%
33 jaar verandering	-40.69%
5 jaar verandering	6.54%
Verandering sinds IPO	1,008.00%

Recent nieuws en updates

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

Rendement voor aandeelhouders

	SYNT	SE Healthcare Services	SE Markt
7D	0%	-2.4%	-1.4%
1Y	-13.4%	39.6%	20.7%

Rendement versus industrie: SYNT presteerde slechter dan de Swedish Healthcare Services -sector, die het afgelopen jaar een rendement van 39.6 % opleverde.

Rendement versus markt: SYNT presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 20.7 % opleverde.

Prijsvolatiliteit

Is SYNT's price volatile compared to industry and market?
SYNT volatility
SYNT Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.0%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	10.8%
10% least volatile stocks in SE Market	3.2%

Stabiele aandelenkoers: SYNT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van SYNT in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	37	Ulrik Harrysson	www.syntheticmr.com

SyntheticMR AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van SyntheticMR zich tot de beurswaarde?
SYNT fundamentele statistieken
Marktkapitalisatie	SEK 1.15b
Inkomsten(TTM)	SEK 10.01m
Inkomsten(TTM)	SEK 94.37m

115.3x

Koers/Winstverhouding

12.2x

P/S-verhouding

Is SYNT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SYNT resultatenrekening (TTM)
Inkomsten	SEK 94.37m
Kosten van inkomsten	SEK 30.33m
Brutowinst	SEK 64.05m
Overige uitgaven	SEK 54.03m
Inkomsten	SEK 10.01m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

May 21, 2024

Winst per aandeel (EPS)	0.24
Brutomarge	67.86%
Nettowinstmarge	10.61%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SYNT op de lange termijn?

Bekijk historische prestaties en vergelijking

SYNT Overzicht aandelen

Beloningen

Risicoanalyse

SyntheticMR AB (publ) Concurrenten

OM:RAY B

SEK 5.2b

OM:PTRK

SEK 193.5m

OM:KONT

SEK 98.7m

OM:SECT B

SEK 54.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

Recent updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors